<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640961</url>
  </required_header>
  <id_info>
    <org_study_id>Cingal 20-02</org_study_id>
    <nct_id>NCT04640961</nct_id>
  </id_info>
  <brief_title>Study of Cingal® for Symptomatic Relief of Osteoarthritis of Shoulder Joint</brief_title>
  <official_title>A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (CINGAL®) to Provide Symptomatic Relief of Osteoarthritis of Shoulder Joint</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anika Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anika Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Trial will obtain clinical data to support an expanded indication for a single injection&#xD;
      of Cingal® used for the symptomatic relief of osteoarthritis in the shoulder joint.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CINGAL® is a chemically cross-linked sodium hyaluronate combined with Triamcinolone&#xD;
      Hexacetonide supplied as a 4-mL unit dose in a 5-mL glass syringe. Cingal will be injected&#xD;
      into the intraarticular (IA) space of the index hip using an 18-21-gauge needle. It is used&#xD;
      for the symptomatic relief of osteoarthritis in the shoulder joint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of index shoulder Numerical Rating Scale (NRS) pain</measure>
    <time_frame>6 months</time_frame>
    <description>(0 to 10 with 0 No Pain and 10 Worst Pain) on walking from baseline to 6 months post injection.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Osteoarthritis, Shoulder</condition>
  <arm_group>
    <arm_group_label>Cingal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cingal</intervention_name>
    <description>CINGAL® is a chemically cross-linked sodium hyaluronate combined with Triamcinolone Hexacetonide supplied as a 4-mL unit dose in a 5-mL glass syringe.</description>
    <arm_group_label>Cingal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Screening Inclusion Criteria&#xD;
&#xD;
          1. Age 18 years or older&#xD;
&#xD;
          2. Body Mass Index (BMI) ≤ 35 kg/m2&#xD;
&#xD;
          3. Diagnosis of symptomatic osteoarthritic joint in the index shoulder (Kellgren-Lawrence&#xD;
             grade I to III or Guyette grade I to III) to be treated with CINGAL injection.&#xD;
&#xD;
          4. Failed conservative treatment for joint osteoarthritis.&#xD;
&#xD;
          5. NRS pain ≥4 and ≤9 in the index shoulder.&#xD;
&#xD;
          6. Subject must be willing to abstain from other treatments of the index shoulder for the&#xD;
             duration of the study.&#xD;
&#xD;
          7. Subject is willing to discontinue all analgesics including NSAIDs, except&#xD;
             acetaminophen/paracetamol, at least seven days before the treatment injection and&#xD;
             through the completion of the study.&#xD;
&#xD;
          8. Subject is willing to use only acetaminophen/paracetamol (up to a maximum of 4.0 grams&#xD;
             per day per the package insert) for the treatment of joint pain for the duration of&#xD;
             the study. At least forty-eight hours prior to the Baseline Visit and each follow-up&#xD;
             assessment, the subject is willing to discontinue use of acetaminophen/paracetamol.&#xD;
&#xD;
          9. Subject is willing to maintain a stable dose of oral glucosamine and/or chondroitin&#xD;
             sulfate products throughout the study, if taken prior to signing the informed consent&#xD;
             form (ICF).&#xD;
&#xD;
         10. Able and willing to provide signed informed consent.&#xD;
&#xD;
        Baseline Inclusion Criteria&#xD;
&#xD;
        1. NRS pain ≥4 and ≤9 in index shoulder&#xD;
&#xD;
        Screening Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity to any of the ingredients in the hyaluronan or&#xD;
             corticosteroids&#xD;
&#xD;
          2. Infection or skin disease in the area of the injection site or index shoulder&#xD;
&#xD;
          3. NRS pain &gt; 3 in the contralateral shoulder&#xD;
&#xD;
          4. Subject received an injection of Hyaluronic Acid (HA) and/or steroid in either joint&#xD;
             within 6 months of signing the informed consent form (ICF). A subject will be excluded&#xD;
             if they are planning to receive an HA or steroid injection (other than the study&#xD;
             injection) in either joint during the course of this study.&#xD;
&#xD;
          5. Known inflammatory or autoimmune disorders (including rheumatoid arthritis, gout), or&#xD;
             other pre-existing medical conditions that, in the opinion of the investigator, could&#xD;
             impact treatment of the index shoulder or affect the ability of the subject to&#xD;
             accurately complete the study questionnaires and comply with the study requirements.&#xD;
&#xD;
          6. Subject is taking medications at the time of signing the ICF which could interfere&#xD;
             with the treatment procedure, healing and/or assessments. This includes but is not&#xD;
             limited to oral or injectable anticoagulant treatments, anti-aggregant platelet&#xD;
             treatment, chronic opioid analgesics. Low dose aspirin used for cardiovascular&#xD;
             protection is allowed if a stable regimen is maintained for the duration of the study.&#xD;
&#xD;
          7. Subjects who had an oral, intramuscular, intravenous, rectal suppository or topical&#xD;
             (excluded in index shoulder only) corticosteroid within 30 days of signing the ICF are&#xD;
             excluded. Topical corticosteroid use at any site other than the index joint is&#xD;
             allowed.&#xD;
&#xD;
          8. Significant trauma to the index shoulder within 26 weeks of screening.&#xD;
&#xD;
          9. Chronic use of narcotics or cannabis.&#xD;
&#xD;
        Baseline Exclusion Criteria&#xD;
&#xD;
          1. Subject has a decrease of ≥ 2 in the NRS pain from Screening to Baseline in the index&#xD;
             shoulder.&#xD;
&#xD;
          2. Subject has a contraindication to continue with the study treatment injection based on&#xD;
             the visual appearance of the synovial fluid aspirate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adrian Orr</last_name>
    <phone>781-457-9200</phone>
    <email>aorr@anika.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Krajská zdravotní, a.s. - Masarykova nemocnice Ústí nad Labem, o.z.</name>
      <address>
        <city>Ústí Nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tomas Novotny, Ph.D. MD</last_name>
    </contact>
    <investigator>
      <last_name>Tomas Novotny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NZOZ MEDI-SPATZ M.Spatz</name>
      <address>
        <city>Gliwice</city>
        <zip>44-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Lukasik, MD</last_name>
    </contact>
    <investigator>
      <last_name>Piotr Lukasik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Przychodnia Rodzinna na Sadowej</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>SPORTO sp. z o.o</name>
      <address>
        <city>Łódź</city>
        <zip>90-038</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcin Domzalski, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marcin Domzalski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sodium Hyaluronate</keyword>
  <keyword>Triamcinolone Hexacetonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

